Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
1.The relationship between the angiotensinogen (AGT) T174M, angiotensin converting enzyme (ACE) insertion/deletion (I/D) and the angiotensin II type 1 receptor (AT1) genetic markers and left ventricular hypertrophy was examined in normal subjects and those with aortic stenosis.2.
|
8800593 |
1996 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Angiotensinogen gene M235T polymorphism predicts left ventricular hypertrophy in endurance athletes.
|
10440164 |
1999 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensinogen (AGT), the precursor of angiotensin II and a rate limiting factor in the renin-angiotensin system, is implicated in left ventricular hypertrophy, as angiotensin II is a potent stimulator of cardiac growth.
|
16280278 |
2005 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Angiotensinogen (AGT), the precursor of angiotensin II and a rate limiting factor in the renin-angiotensin system, is implicated in left ventricular hypertrophy, as angiotensin II is a potent stimulator of cardiac growth.
|
16280278 |
2005 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Angiotensinogen M235T and T174M polymorphisms have individually been associated with elevated levels of plasma angiotensinogen, hypertension, and left ventricular hypertrophy.
|
17145981 |
2007 |
Left Ventricular Hypertrophy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes.
|
18679781 |
2008 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
CTD_human |
A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes.
|
18679781 |
2008 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
ACE is responsible for the generation of angiotensin II, which is implicated in the development of left ventricular hypertrophy, an independent risk factor for morbidity and mortality in hypertension.
|
7820539 |
1994 |
Left Ventricular Hypertrophy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Adrenomedullin modulates hemodynamic and cardiac effects of angiotensin II in conscious rats.
|
14751847 |
2004 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
CTD_human |
Adrenomedullin modulates hemodynamic and cardiac effects of angiotensin II in conscious rats.
|
14751847 |
2004 |
Left Ventricular Hypertrophy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Angiotensin-(1-7) ameliorates myocardial remodeling and interstitial fibrosis in spontaneous hypertension: role of MMPs/TIMPs.
|
20837116 |
2010 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
CTD_human |
Angiotensin-(1-7) ameliorates myocardial remodeling and interstitial fibrosis in spontaneous hypertension: role of MMPs/TIMPs.
|
20837116 |
2010 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme and angiotensinogen genes in patterns of left ventricular hypertrophy and in diastolic dysfunction.
|
8582095 |
1996 |
Left Ventricular Hypertrophy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Cardiac hypertrophy in aryl hydrocarbon receptor null mice is correlated with elevated angiotensin II, endothelin-1, and mean arterial blood pressure.
|
14644620 |
2003 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
CTD_human |
Cardiac hypertrophy in aryl hydrocarbon receptor null mice is correlated with elevated angiotensin II, endothelin-1, and mean arterial blood pressure.
|
14644620 |
2003 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chronically instrumented pigs received angiotensin II infusion for4weeks to induce chronic hypertension (133 ± 7 mmHg vs 98 ± 5 mmHg for mean arterial pressure at Day 28 vs 0, respectively) and LV hypertrophy.
|
31051181 |
2019 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Effects of a changeover from other angiotensin II receptor blockers to olmesartan on left ventricular hypertrophy in heart failure patients.
|
27722772 |
2017 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Eight chronically instrumented pigs receiving continuous angiotensin II infusion during 28days to induce chronic hypertension and LV hypertrophy.
|
29196088 |
2018 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Exciting new discoveries concerned with polymorphisms of genes coding for angiotensin converting enzyme (ACE) and angiotensinogen suggest that Ang II may be genetically associated with increased risk for myocardial infarction, hypertension and left ventricular hypertrophy.
|
8583476 |
1995 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Five genetic polymorphisms of the RAAS (ACE, AGTR1, AGT, CMA, CYP11B2) were analyzed in all patients and the results of genetic analysis were correlated to severity of AS and LVH to determine the importance of the polymorphisms for LVH.
|
11275936 |
2001 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Frequency of IT genotype of ATG gene in patients with LVH was significantly (P<0.01) greater than that in normal controls or marginally (P=0.1) higher than that in patients without LVH.
|
10646957 |
2000 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, neither ID ACE-gene polymorphism nor ATI-receptor gene and angiotensinogen gene polymorphism was associated with LVH.
|
11688760 |
2001 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the possibility that RAGE-mediated signaling is involved in angiotensin II (Ang II)-induced cardiac left ventricular hypertrophy has yet to be investigated.
|
29796842 |
2018 |
Left Ventricular Hypertrophy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, vasodilators and diuretics, which stimulate adrenoceptor activity and increase angiotensin II levels, were found to be less effective in reversing LV hypertrophy.
|
1380616 |
1992 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, the induction of human cardiac fibroblasts (HCF) and human umbilical vein endothelial cells (HUVEC) with the LVH mediator angiotensin II enabled us to investigate uremic LVH progression in vitro.
|
19094982 |
2009 |